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 Abstract 
Background  
Traditionally, single-unit red blood cell transfusions were believed to be 
insufficient to treat anemia, but recent data suggest that they may lead to a safe 
reduction of transfusion requirements. We tested this hypothesis by changing from 
double- to single-unit red blood cell transfusion policy. 
 
Design and methods 
We performed a retrospective cohort study in patients with hematological 
malignancies receiving intensive chemotherapy or hematopoietic stem cell 
transplantation. The major endpoints were the reduction in the total number of red 
blood cell units per therapy cycle and per day of aplasia. The study comprised 139 
patients receiving 272 therapy cycles. A total of 2212 red blood cell units were 
administered in 1548 transfusions.  
 
Results  
During the double- and single-unit period one red blood cell unit was 
transfused in 25% and 84% of the cases and the median number of red blood cell 
units per transfusions was 2 and 1, respectively. Single-unit transfusion led to a 25% 
reduction of the red blood cell requirements per therapy cycle and 24% per aplasia 
day, but was not associated with a higher outpatient transfusion frequency. In 
multivariate analysis, single-unit transfusion resulted in reduction of 2.7 red blood cell 
units per treatment cycle (p=0.001). The pretransfusion hemoglobin levels were lower 
during the single-unit period (median 61g/L vs. 64g/L) and more transfusions were 
administered in patients with hemoglobin values ≤ 60gl/L (47% vs. 26%). Neither 
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 more severe bleedings nor platelet transfusions were recorded during the single-unit 
period and the overall survival was similar in both cohorts.  
 
Conclusions 
Implementing a single-unit transfusion policy saves 25% of red blood cell units 
and thereby reduces the risks associated with allogeneic blood transfusions. 
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 Introduction 
 Single-unit red blood cell (RBC) transfusions were extensively criticized in the 
past. It was believed that RBC transfusions were useless if the transfusion 
requirements could be satisfied by infusion of one RBC unit and that patients were no 
more in need of the transfusion than their donors1-3. However, data on the risk or 
benefit of a single-unit transfusion strategy is scarce and most evidence derives from 
studies analyzing perioperative single-unit RBC transfusions in surgical and 
obstetrical populations3-7. The essential problem of all these studies is that they 
introduced a considerable selection bias by simply comparing the pretransfusion 
hemoglobin levels and the transfusion requirements of patients having received one 
or two RBC units. Not surprisingly, these studies showed that patients with single-unit 
transfusions had higher or even normal pretransfusion hemoglobin levels when 
compared to those receiving double-unit transfusions, and for the vast majority of 
these single-unit transfusions todays guidelines would not have recommended RBC 
transfusions at all. However, no study has evaluated the effect of double- or single-
unit RBC transfusion in patients with hyporegenerative anemia with comparable 
pretransfusion hemoglobin levels and there is no evidence supporting double-unit 
RBC transfusions in patients without active bleeding.  
A restrictive transfusion policy with stringent transfusion triggers and a 
cautious use of blood products is the single most effective measure to reduce 
transfusion requirements and given the scarcity and inherent risks of allogeneic blood 
products a reduction of blood transfusions is of major health and economic interest. 
Reducing the volume per transfusion may save a considerable number of RBC units 
thereby reducing the patients’ exposure to allogeneic blood products8. However, 
despite a lack of studies, most guidelines recommend double-unit transfusions, while 
only few more recent guidelines allow single-unit RBC transfusions in the absence of 
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 active bleeding9-14. Nonetheless, surveys on transfusion practices have shown that 
more than 90% of the physicians currently transfuse two RBC units simultaneously 
showing that they have not yet implemented this new transfusion policy15-18.  
 Since data suggest that single-unit transfusions may considerably reduce the 
total RBC requirements we changed our policy for hospitalized patients without active 
bleeding from double- to single-unit RBC transfusions. The current study analyzed 
the effect of the new RBC transfusion policy with regards to the overall RBC 
requirements and the transfusion efficiency, the adherence to the transfusion policy, 
as well as safety aspects including the bleeding risk and the number of transfused 
platelets. 
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 Design and Methods 
Study population and protocol 
 This single-center study was performed in the leukemia and the hematopoietic 
stem cell transplantation units of the University Hospital Zurich. Patients were eligible 
if they were older or equal to 16 years, received intensive chemotherapy, autologous 
or allogeneic hematopoietic stem cell transplantation for hematological malignancies 
and were treated as inpatients. Patients with AML were treated according to the 
HOVON 42 protocol and patients with acute promyelocytic leukemia according to the 
APL 2000 study19, 20. Allogeneic hematopoietic stem cell transplantation was 
performed in a laminar flow unit using standard myeloablative- and non-
myeloablative conditioning regimens. Patients receiving chemotherapies 
predominantly as outpatients were excluded from the study. The local ethical 
committee approved the study and waived the requirement for written informed 
consent due to the retrospective nature of the study.  
 In 2008 we changed our RBC transfusion policy by dispensing only one RBC 
unit at the time from the blood bank. The single-unit transfusion policy was 
established in all hospital wards with the exception of the intensive care units, the 
emergency wards and the operating rooms. More than one RBC unit was dispensed 
only if explicitly prescribed by the treating physician (e.g. in cases with active 
bleeding). To evaluate the effect of the new transfusion policy, we performed a 
retrospective single-center analysis from July 2007 to December 2009 comparing two 
cohorts of patients receiving either double- or single-unit RBC transfusions. We 
restricted the analysis to patients with hematological malignancies receiving intensive 
chemotherapies or hematopoietic stem cell transplantation, as the transfusion 
requirements in these patients are high and the transfusion triggers predictable. In 
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 order to avoid a selection bias, the analysis also included all transfusions given in the 
intensive care units, emergency wards and operation rooms unless stated otherwise. 
 
Transfusion policies  
 All patients had daily white blood cell and platelet counts, hemoglobin, and 
hematocrit determinations. The RBC transfusion trigger was a morning hemoglobin 
level ≤60g/L or the presence of anemia symptoms such as fatigue, resting dyspnea, 
and dizziness. All RBC units were leukocyte-reduced by means of filtration before 
storage. The maximally tolerated leukocyte count after filtration was <1x106 
leukocytes/unit. The volume of the RBC units ranged from 200 to 350mL and the 
maximal age of RBC was 42 days according to the Swiss legislation. RBC units were 
generally not irradiated, but all patients with autologous or allogeneic HSCT or 
chemotherapies with purine analogues received exclusively cellular blood products 
that were irradiated with 25 Gy. 
 Platelets were transfused as previously described21. All platelet units were 
leukocyte-reduced by means of filtration before storage and contained ≥2.5x10 11 
platelets. All patients with morning platelet counts ≤5x10 9/L received prophylactic 
platelet transfusions irrespective of bleeding signs. In case of fever or during HSCT, 
the platelet transfusion trigger was ≤10x10 9/L. There was no change of the platelet 
transfusion policy in the two periods.  
 
Measurements and definitions 
 We analyzed the reduction in the total number of RBC units per therapy cycle 
and per day of aplasia as well as determinants related to transfusion efficiency and 
safety, i.e. the number of platelet transfusions, bleeding incidence, outpatient RBC 
transfusions, the overall survival and adherence to transfusion policy.  
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  The hemoglobin increment was determined by subtracting the morning 
hemoglobin value one day after the transfusion from the one directly before 
transfusion. Therapy cycles lasted from the first day of chemotherapy or the day of 
HSCT until neutrophil recovery (absolute neutrophil count (ANC) > 0.5x109/L for 3 
consecutive days). The time until RBC recovery lasted from the first day of 
chemotherapy or the day of HSCT until the reticulocytes increased to > 1%. The 
duration of aplasia time was from the first day when ANC were ≤ 0.5x109/L until ANC 
recovery. Major bleeding episodes requiring RBC transfusions or non-elective 
interventions were analyzed from the patient charts. Due to the retrospective 
assessment, minor bleedings could not be reliably assessed and were not evaluated 
in this study. The adherence to the transfusion policy was displayed as the 
percentage of transfusions given as single-unit or double-unit in the respective 
transfusion periods. Risk assessment for AML was made according to the HOVON 
risk score, for patients with ALL according to the GRAALL 2005 study. Patients 
receiving allogeneic transplantation other than in first complete remission or in first 
chronic phase for CML were considered as poor risk as well as all patients receiving 
HSCT for other malignancies. 
 
Statistical analysis 
 Baseline characteristics are displayed as proportions or medians with 
interquartile ranges (IQR). Patients with double- and single-unit RBC transfusions 
were compared using Mann-Whitney-U test for continuous variables or chi-squared 
test for categorical data, as appropriate. To evaluate the independent association 
between the transfusion policy and the number of RBC units/therapy we applied 
multiple linear regression modelling. We controlled for the aplasia time during a 
therapy cycle as important determinant for the total requirement of RBC units and 
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 other potential confounders such as patients’ age at diagnosis, and hemoglobin 
levels prior to transfusion and the proportion of irradiated RBC units. The model was 
further adjusted for the clustering of the data (i.e. repeated procedures in the same 
patients) by applying robust standard errors22.  
 The overall survival was calculated from the beginning of the chemotherapy or 
the day of HSCT until death or last follow-up. The survival observation of patients 
receiving more than one therapy cycle was censored at the beginning of the next 
cycle. Survival differences between the two transfusion policy groups were estimated 
with the method of Kaplan and Meier and compared by log rank test as well as by 
using multivariate stepwise Cox regression analysis further controlling for potential 
confounders. All reported p-values are two-sided, and p<0.05 were assumed to be 
statistically significant.  
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 Results 
Baseline characteristics 
 The study comprised 139 patients receiving 272 therapy cycles. Baseline 
characteristics are shown in table 1. They were equally distributed among the 
patients in the single- and double-unit period. The median age of the study 
population was 49 years (IQR 37-58), 72 (52%) of the patients were male and 67 
(48%) female. The majority of the patients were treated for acute myelogenous 
leukemia (AML, 102, 73%), acute lymphoblastic leukemia (ALL, 17, 12%) or Hodgkin 
and non-Hodgkin lymphoma (12, 9%). Intensive chemotherapy consisted of induction 
(136, 50%), consolidation (35, 13%) and reinduction (16, 6%). The remaining 
therapies were allogeneic (81, 30%) or autologous HSCT (4, 1%). The median time 
from start of the chemotherapy or from HSCT until neutrophil recovery was 23 days 
(IQR: 20-28) and the median aplasia time 17 days (IQR: 12-23). The median time 
until reticulocyte recovery was 27 days (IQR: 24-34). 
 
RBC transfusions 
 Table 2 displays the results of the RBC transfusions in more details. A total of 
2212 RBC units were given in 1548 transfusions. During the double-unit period 1242 
(56%) RBC units were transfused in 134 (49%) therapy cycles and during the single-
unit period 970 (44%) RBC units were transfused in 138 (51%) cycles. Ninety-six 
percent of the RBC transfusions were ABO identical and 4% ABO compatible. During 
the study period, only one severe transfusion reaction was reported (transfusion-
associated volume overload, 1/1548, 0.064%). The median number of RBC units 
transfused per therapy cycle was 7 (IQR: 4-11) with patients undergoing conventional 
intensive chemotherapy requiring significantly more RBC units (8, IQR: 5-12) as 
compared to HSCT (4, IQR: 2-8; p<0.001). However, there was no significant 
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 difference in the RBC transfusion requirements between chemotherapy and HSCT 
when analyzed per aplasia day (p=0.832). The median number of transfused RBC 
per aplasia day was 0.38 units (IQR, 0.25-0.63). 
During one transfusion the median number of RBC units administered was 2 
(IQR: 1-2) in the double- and 1 (IQR: 1-2) in the single-unit period (p<0.001). To 
avoid a selection bias, this analysis also included all transfusions given to patients in 
the intensive care unit and the operation room (n=133, 9%), while there were no 
transfusions in the emergency ward. However, as shown in Table 2, exclusion of 
RBC units given in the ICU setting did not significantly change the results.  
During 20 therapy cycles no RBC units were transfused at all. Eight cycles 
without RBC transfusion support were administered during the double- and 12 during 
the single-unit period. Fifteen of these therapy cycles were allogeneic HSCT with 
reduced-intensity (7) or myeloablative conditioning (8). The median aplasia time in 
this group was 8 days (IQR 5-12). The remaining five therapy cycles were 
consolidation chemotherapies for AML with a median aplasia time of 9 days (IQR 7-
12). The aplasia time was significantly shorter in therapy cycles without transfusions 
as compared to those with transfusions (median 8 vs. 20 days, p<0.001).  
 
The effect of the single-unit RBC transfusion policy 
As shown in figure 1, the change of the transfusion policy led to a 25% 
reduction of the transfused RBC units per therapy cycle (double-unit: median 8, IQR 
4-13; single-unit: median 6, IQR 3-10; p=0.003). Normalization of the transfusion 
requirements to one aplasia day resulted in a 24% reduction of the RBC transfusions 
in the single-unit period. During the double-unit period, a median of 0.46 RBC (IQR: 
0.30-0.72) units were transfused per aplasia day, while a median of 0.35 (IQR: 0.20-
0.50) RBC units were transfused during the single-unit period (p<0.001).  
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 Even though the median RBC transfusions per aplasia day were less in the 
single unit period, the time between transfusions was also less in the single unit 
period. Although there was no difference in the median number of days between the 
two groups, the mean time between transfusions was significantly shorter in the 
single-unit period (3.25 vs. 4.05 days, p<0.001). The difference between the two 
groups was approximately 20% indicating that the change to a single-unit transfusion 
policy moderately increases the workload for the hospital health care employees. 
Patients during single-unit period had slightly lower hemoglobin levels at the 
time of discharge (74 g/L vs. 78 g/L, p<0.001), whilst there was no difference at the 
beginning of the therapy (89 vs. 89 g/L). However, the lower hemoglobin levels at the 
time of discharge did not translate into a higher RBC transfusion requirements as 
outpatients (Double-unit: median 0 (IQR: 0-1, range: 0-21) RBC units; single-unit: 
median 0 (0-0, range: 0-45) RBC units, p=0.819). Likewise, the time until RBC 
recovery was similar in the two groups.  
The effect of the transfusion policy was further confirmed in a linear regression 
model adjusting for confounding factors and clustering of multiple transfusions in the 
same patient. The change from double- to single-unit transfusion policy remained 
independently associated with a significant reduction of 2.7 units (95%-CI -4.3;-1.1, 
p=0.001) per therapy cycle (table 3). As expected, increasing aplasia time was 
associated with higher RBC transfusion requirements, while the gender and age of 
the recipients, irradiation of the RBC as well as the haemoglobin levels prior to 
transfusion did not influence the transfusion requirements.  
 
Adherence to the single-unit RBC transfusion policy 
Adherence to the assigned RBC transfusion strategy was analyzed by 
calculating the percentage of correctly administered RBC transfusions in the two 
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 study periods (Figure 2). Single units were transfused in 25% of the cases during the 
double- and in 84% during the single-unit period. In 130 transfusions (16%) during 
the single-unit period two or more RBC units were administered consecutively. The 
reason for the non-adherence to the single-unit transfusion policy was evaluable in 
63% of the cases. Lack of knowledge of the new transfusion policy (21%), 
hospitalization in the ICU (15%), bleeding events (13%), low hemoglobin values 
(11%), or transfusions before discharge (3%) were the major reasons for breaking 
the transfusion policy. Lack of knowledge was primarily seen within the first 4 months 
after changing the transfusion policy or if new physicians prescribed RBC 
transfusions. In the remaining 37% of the transfusions there was no clear indication 
for the non-adherence of the transfusion policy. 
 
RBC transfusion triggers  
The RBC transfusion trigger in hospitalized patients was ≤ 60g/L in the 
absence of anemia symptoms during both periods. A total of 567 (37%) RBC 
transfusions were given in patients with morning hemoglobin levels lower or equal to 
60g/L, 778 (51%) with 61-70g/L, 164 (11%) with 71-80g/L, and 19 (1%) with 
hemoglobin levels >80g/L. During the single-unit period, significantly more 
transfusions were administered in patients with hemoglobin values lower or equal to 
60gl/L (26% vs. 47%, p<0.001), while more patients received RBC transfusions with 
hemoglobin levels between 61-80g/L during the double unit period (74% vs. 53%). 
This also resulted in a significantly lower hemoglobin level at the time of RBC 
transfusions during the single-unit period (median 61 (IQR, 58-65) g/L as compared 
to the double-unit period (median 64, (IQR: 60-69) g/L (p<0.001).  
 
Safety of single-unit RBC transfusions 
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  The lower hemoglobin levels may result in a higher bleeding risk due to altered 
rheological properties in severely anemic patients. To exclude this, we analyzed the 
bleeding episodes in the two cohorts and the total number of transfused platelets. 
Severe bleedings occurred in 18 therapy cycles. During these cycles 213 RBC units 
were administered which equals 14% of the total RBC units. There was no significant 
difference in the number of therapy cycles with severe bleeding episodes in the 
double-unit period (7, 5.2%) and single-unit period (11, 8.0%, p=0.362) and the 
median number of platelets transfused per therapy cycle was 5 (2-9) and 5 (3-9) in 
the double- and single-unit period (0.896). 
 Finally, as shown in figure 3, we evaluated the overall survival as a measure 
for safety after chemotherapy and HSCT. Patients receiving more than one therapy 
cycle were censored at the time of the next cycle. The median observation time was 
78 (9-1087) days. The 30- and 100-day survival probability was 98% (95%-
confidence interval 96-99%) and 89% (84-94%) without differences between the two 
groups (p=0.893) indicating that the transfusion policy had no influence on the overall 
survival.  
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 Discussion 
 Our retrospective cohort study demonstrates for the first time that a change 
from double- to single-unit RBC transfusion policy is safe and associated with a 
reduction of 25% of RBC transfusion requirements in a population with hemato-
oncological disorders. This finding demonstrates that the long-standing dogma that 
two RBC units are necessary for an adequate hemoglobin increase has to be 
critically revised. 
 Although each year over 75 million units of blood are transfused worldwide, 
both the optimal number of RBC units per transfusion and the best RBC transfusion 
trigger remain controversial11. As a consequence, physicians have to rely primarily on 
clinical experience rather than published data for their decision-making. In the last 
decades, the general recommendation was to give two RBC units simultaneously, 
while single-unit RBC transfusions were discredited as useless1-3 and some authors 
even suggested to critically revise the local transfusion program if more than 50% of 
the RBC transfusions were given as single-units23.  
However, this was mainly based on few studies specifically analyzing the 
effect of single-unit transfusions. The main findings of these studies were that in 
surgical or obstetric units approximately 25% of all transfusions were single-units. 
However, over 50% of all patients received single-unit transfusions at hemoglobin 
levels >100g/L and approximately 80% of all transfusions were judged to be 
questionable or not indicated5-7. The studies share several limitations: i) they were 
performed several decades ago, when the transfusion practices as well as the blood 
products considerably differed from today’s transfusion technologies. ii) All studies 
analyzed single-unit RBC transfusion by comparing patients having received one or 
two RBC units without clear transfusion guidelines. In the vast majority of patients 
receiving only one RBC unit the transfusions were indeed not indicated because the 
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 pretransfusion hemoglobin values were close to normal. iii) None of the studies 
analyzed single-unit RBC transfusions in a non-surgical population. 
In contrast, a single-center analysis found that almost 50% of all transfusions 
were given as single-units, 62% of which were indicated24. They concluded that it 
would be an error to give two units, if one unit is sufficient to correct anemia. One 
more recent study theoretically analyzed the effect of transfusing only one RBC unit 
at the time concluding that a single-unit RBC transfusion strategy has a considerable 
potential to save RBC units and that this was more pronounced when applying lower 
transfusion triggers8. Our current study analyzed for the first time two cohorts of 
patients who were subjected to either transfusion policy, thus avoiding the selection 
bias of earlier studies. The limitations of the study are the retrospective single-center 
analysis, the lack of standardized bleeding assessments and the lack of a quality of 
life assessment of the patients during the therapy.  
Some studies have suggested that a lower hematocrit in the peripheral blood 
is associated with a poorer marginalization of the circulating platelets and 
consequently with an increased bleeding risk15. Thus, one major concern at the time 
of changing the transfusion policy in our institution was an increased risk for major 
bleedings and higher platelet transfusion requirements. Our data, however, reveal no 
evidence for higher bleeding rates or higher platelet requirements in the single-unit 
transfusion group.  
Moreover, some concerned the higher workload for the health care 
professionals due to a more frequent transport of RBC units from the local blood 
bank. It is difficult to assess the exact costs of this blood transport. Indeed, the time 
between two RBC transfusions was approximately 20% shorter during the single-unit 
period leading to a higher transfusion frequency and potentially to a higher workload 
of the health care professionals. However, it is not clear whether the reduced 
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 workload due to fewer transfusions outweighs the workload of the blood transport. 
And even if the workload is moderately increased, we believe that the higher 
workload is justified given the inherent risk of each blood transfusion and the hospital 
logistics for blood supply should be improved rather than giving unnecessary blood 
transfusions to patients.  
As for the workload, it is difficult to provide exact data on the real costs of 
transfusions of blood products. A recently published study meticulously analyzed the 
real costs of RBC transfusion in four hospitals25. In this study, an activity-based 
costing model was constructed taking into considerations tasks and resource 
consumption (materials, labor, third-party services, capital) related to blood 
administration. The median costs of one RBC transfusion in surgical patients were 
$760.82± 293.74. In the current study, each patient received a median of 15 RBC 
units during the whole treatment resulting in a total amount $11412 for RBC 
transfusions. Thus, a 25% reduction leads to savings of $2853 per patient.  
 The best transfusion trigger is a long-standing matter of debate. It is generally 
acknowledged that patients should receive RBC transfusions if the hemoglobin is 
lower or equal to 60g/L26, 27. A number of studies have analyzed transfusion triggers 
in ICU and recently in cardiac surgery patients showing that a restrictive transfusion 
policy resulted in a significant reduction of the transfusion requirements with 
comparable or even superior mortality rates28-33. A meta-analysis indicated that the 
use of a restrictive transfusion trigger resulted in an average saving of 0.93 units of 
red cells per transfused patient26. In patients with hemato-oncological disorders only 
limited data exist regarding the optimal transfusion threshold34. In patients receiving 
intensive chemotherapies for AML the requirements differed considerably between 
centers and a more restrictive transfusion threshold seems to be feasible in these 
patients35, 36.  
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  An interesting finding of our study shows that the hemoglobin levels directly 
before transfusion of RBC were slightly lower during the single unit period despite 
similar transfusion guidelines in the two periods. Likewise, the hemoglobin levels at 
the time of discharge were slightly lower, but this difference did not translate into a 
higher transfusion rate as outpatients. These findings may indicate that anemia 
during transfusion dependency is better tolerated in the absence of large fluctuations 
between the peak and trough hemoglobin caused by the administration of 2 RBC 
units. In the situation of fewer clinical symptoms the patients may also better tolerate 
the lower transfusion threshold. It seems rather unlikely that more patients suffered 
from fatigue and anemia symptoms during the single-unit period, since these 
symptoms were considered as transfusion triggers throughout the study duration. 
However, we did not perform a proper assessment of the fatigue and the quality of 
life and therefore we cannot draw definite conclusions.  
 In conclusion, this is the first study indicating that a change to a single-unit 
transfusion policy can safely reduce the RBC transfusion requirements by 
approximately 25% without changing the transfusion triggers. Our data suggest that a 
single-unit RBC transfusion policy is effective and cost saving and is not associated 
with an increased risk for the patients, but with a moderately elevated workload for 
the health care professionals. Given the scarceness of allogeneic blood products and 
the inherent risk of all blood transfusions, these results may have a major impact in 
the transfusion strategies for patients with hyporegenerative anemias. These data 
have to be confirmed in prospective randomized trials. 
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Tables 
Table 1. Baseline Characteristics.   
 
 Transfusion strategy  
 Double Single P value 
Patients* 77 (55) 62 (45)  
Cycles 134 (49) 138 (51)  
Age$ 51 (41-58) 47 (33-56) 0.126 
Gender   0.470 
Male 42 (54) 30 (48)  
Female 35 (46) 32 (52)  
Disease   0.123 
AML 56 (73) 46 (74)  
ALL 6 (8) 11 (18)  
Lymphoma 8 (10) 4 (6)  
Others 7 (9) 1 (2)  
Disease stage   0.450 
Good 28 (21) 37 (27)  
Intermediate  33 (25) 35 (25)  
Poor 73 (54) 66 (48)  
Therapy   0.559 
Induction 67 (50) 69 (50)  
Consolidation 15 (11) 20 (15)  
Reinduction 6 (5) 10 (7)  
Allogeneic HSCT 43 (32) 38 (27)  
Autologous HSCT 3 (2) 1 (1)  
Duration of therapies$  
Time of aplasia 17 (12-22) 18 (12-23) 0.358 
CT until end of aplasia 23 (20-27) 23 (20-28) 0.599 
CT until reticulocytes >1% 29 (23-35) 27 (24-32) 0.082 
*Statistics are number and percentages unless otherwise indicated 
$ Median (Interquartile range) 
AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CT, 
Chemotherapy; HSCT, hematopoietic stem cell transplantation 
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 Table 2. RBC transfusions.   
 Transfusion strategy  
 Double Single P value 
 
  
Administered RBC units*    
Total 1242 (56) 970 (44)  
Chemotherapy 922 (54) 791 (46)  
HSCT 320 (64) 179 (36)  
RBC units/transfusion   <0.001 
Mean (SD) 1.76 (0.49) 1.18 (0.47)  
Median (IQR) 2 (1-2) 1 (1-1)  
RBC units/transfusion, excluding ICU transfusions <0.001 
Mean (SD) 1.79 (0.42) 1.14 (0.38)  
Median (range) 2 (2-2) 1 (1-1)  
RBC units/transfusion, excluding severe bleedings <0.001 
Mean (SD) 1.79 (0.43) 1.15 (0.385)  
Median (range) 2 (2-2) 1 (1-1)  
Transfusion trigger (g/L)   <0.001 
 ≤60 181 (26) 386 (47)  
 61-70 406 (57) 372 (45)  
 71-80 107 (15) 57 (7)  
 >80 12 (2) 7 (1)  
 Median (IQR) 64 (60-69) 61 (58-65) <0.001 
Hb increase/transfusion$ 12 (6-17) 7 (4-11) <0.001 
Hb prior to therapy and at discharge$  
Prior 89 (78-104) 89 (74-109) 0.992 
At discharge 78 (72-85) 74 (67-80) <0.001 
Irradiation   <0.001 
No 342 (48) 547 (66)  
Yes 364 (52) 275 (34)  
*Statistics are numbers (percentage) unless otherwise indicated 
$Median (Interquartile range) 
Hb, hemoglobin; HSCT, hematopoietic stem cell transplantation; IQR, interquartile 
range; SD, standard deviation; RBC, red blood cells 
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 Table 3. Multivariate linear regression analysis. 
 
  
 Units/therapy cycle 95%-CI P value 
Transfusion policy -2.7 -4.2;-1.2 0.001 
Aplasia time 0.3 0.2; 0.4 <0.001 
Gender -1.2 -2.6; 0.2 0.100 
Age at diagnosis 0 0.0; 0.1 0.225 
Irradiation of RBC -0.8 -2.4; 0.7 0.294 
Hb prior to transfusion 0.1 -0.1; 0.3 0.255 
Dependent variable: Cumulative units per therapy cycle 
Hb, hemoglobin; RBC, red blood cells 
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Figure legends 
 
Figure 1. Reduction of RBC units per therapy and transfusion-free time. 
 The boxplots display medians, interquartile ranges, and 95% confidence 
intervals. The double RBC-unit period is displayed in light grey and the single-unit 
period in dark grey. A Changing of the transfusion policy led to a 25% reduction of 
the transfused RBC units per therapy cycle (p=0.003). B Normalization to one aplasia 
day resulted in a 24% reduction of the RBC transfusions in the single-unit period 
(p<0.001). C The mean time between two transfusions was 20% longer in the 
double-unit period (p<0.001). 
 
Figure 2. Adherence to the transfusion policy. 
 Adherence to the assigned RBC transfusion strategy was analyzed by 
calculating the percentage of correctly administered RBC transfusions in the two 
study periods. Light grey indicates 1 RBC unit, dark grey 2, and black >2 RBC units 
per transfusion. Single units were transfused in 25% of the cases during the double- 
and in 84% during the single-unit period. 
 
Figure 3. Overall survival according to the RBC transfusion policy. 
 Kaplan-Meier survival estimates in patients during the double- and single-unit 
RBC period. The 30- and 100-day survival probability was 98% (95%-confidence 
interval 96-99%) and 89% (84-94%) without differences between the two groups 
(p=0.893) indicating that the transfusion policy had no influence on the overall 
survival.  
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 Figure 1. Reduction of RBC units per therapy and transfusion-free time. 
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 Figure 2. Adherence to the transfusion policy. 
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 Figure 3. Overall survival according to the RBC transfusion policy. 
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